Prospect of 3D bioprinting over cardiac cell therapy and conventional tissue engineering in the treatment of COVID-19 patients with myocardial injury

Wang, 2020, 2019-Novel coronavirus-related acute cardiac injury cannot Be ignored, Curr Atherosclerosis Rep, 22, 1, 10.1007/s11883-020-00842-y

Rath, 2020, Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection, Clin Res Cardiol, 109, 1491, 10.1007/s00392-020-01683-0

Xia, 2020, Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein, Cell Mol Immunol, 17, 765, 10.1038/s41423-020-0374-2

de Wilde, 2018, Host factors in coronavirus replication, Curr Top Microbiol Immunol, 419, 1

Shi, 2020, Association of cardiac injury with mortality in hospitalized patients with COVID-19 in wuhan, China supplemental content, JAMA Cardiol, 5, 802, 10.1001/jamacardio.2020.0950

Matsushita, 2020, Impact of COVID-19 on the cardiovascular system: a review, J Clin Med, 9, 1407

Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, 56, 105949, 10.1016/j.ijantimicag.2020.105949

Tönnesmann, 2013, Chloroquine cardiomyopathy-a review of the literature, Immunopharmacol Immunotoxicol, 35, 434, 10.3109/08923973.2013.780078

Ma, 2020, Coronavirus disease-2019 (COVID-19) and cardiovascular complications, J Cardiothorac Vasc Anesth

Aggarwal, 2020, Cardiovascular safety of potential drugs for the treatment of coronavirus disease 2019, Am J Cardiol, 128, 147, 10.1016/j.amjcard.2020.04.054

Nishiga, 2020, COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives, Nat Rev Cardiol, 17, 543, 10.1038/s41569-020-0413-9

Chatre, 2018, Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature, Drug Saf, 41, 919, 10.1007/s40264-018-0689-4

Gabay, 2013, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial, Lancet, 381, 1541, 10.1016/S0140-6736(13)60250-0

Qiu, 2019, Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials, Lipids Health Dis, 18, 54, 10.1186/s12944-019-0994-7

Nugent, 2003, Tissue engineering therapy for cardiovascular disease, Circ Res, 92, 1068, 10.1161/01.RES.0000073844.41372.38

Menasché, 2008, Cardiac cell therapy trials: chronic myocardial infarction and congestive heart failure, J Cardiovasc Transl Res, 1, 201, 10.1007/s12265-008-9017-1

Liu, 2021, Advances in 3D bioprinting technology for cardiac tissue engineering and regeneration, Bioact Mater, 6, 1388, 10.1016/j.bioactmat.2020.10.021

Ong, 2018, 3D and 4D bioprinting of the myocardium: current approaches, challenges, and future prospects, BioMed Res Int, 2018, 10.1155/2018/6497242

Ma, 2018, 3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling, Adv Drug Deliv Rev, 132, 235, 10.1016/j.addr.2018.06.011

Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3

Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China, JAMA Intern Med, 180, 934, 10.1001/jamainternmed.2020.0994

Ruan, 2020, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med, 46, 846, 10.1007/s00134-020-05991-x

Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China, JAMA, J Am Med Assoc, 323, 1061, 10.1001/jama.2020.1585

Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, 8, 475, 10.1016/S2213-2600(20)30079-5

Guo, 2020, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 811, 10.1001/jamacardio.2020.1017

Chen, 2020, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ (Clinical research ed.), 368, m1091

Tavazzi, 2020, Myocardial localization of coronavirus in COVID-19 cardiogenic shock, Eur J Heart Fail, 22, 911, 10.1002/ejhf.1828

Zheng, 2020, COVID-19 and the cardiovascular system, Nat Rev Cardiol, 17, 259, 10.1038/s41569-020-0360-5

Wu, 2020, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention, J Am Med Assoc, 323, 1239, 10.1001/jama.2020.2648

Zou, 2020, Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, Front Med, 14, 185, 10.1007/s11684-020-0754-0

Hu, 2021, Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin, Eur Heart J, 42, 206, 10.1093/eurheartj/ehaa190

Chen, 2020, The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2, Cardiovasc Res, 116, 1097, 10.1093/cvr/cvaa078

Alifano, 2020, Renin-angiotensin system at the heart of COVID-19 pandemic, Biochimie, 174, 30, 10.1016/j.biochi.2020.04.008

Verdecchia, 2020, The pivotal link between ACE2 deficiency and SARS-CoV-2 infection, Eur J Intern Med, 76, 14, 10.1016/j.ejim.2020.04.037

South, 2020, COVID-19, ACE2, and the cardiovascular consequences, Am J Physiol Heart Circ Physiol, 318, H1084, 10.1152/ajpheart.00217.2020

Lazaridis, 2020, Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery, Hellenic J Cardiol, 61, 381, 10.1016/j.hjc.2020.05.004

Driggin, 2020, Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic, J Am Coll Cardiol, 75, 2352, 10.1016/j.jacc.2020.03.031

Thygesen, 2019, Fourth universal definition of myocardial infarction (2018), Eur Heart J, 40, 237, 10.1093/eurheartj/ehy462

Bandyopadhyay, 2020, COVID-19 pandemic: cardiovascular complications and future implications, Am J Cardiovasc Drugs, 20, 311, 10.1007/s40256-020-00420-2

Tufan, 2020, COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs, Turk J Med Sci, 50, 620, 10.3906/sag-2004-168

Court, 2002, Clinical review: myocardial depression in sepsis and septic shock, Crit Care (London, England), 6, 500, 10.1186/cc1822

Mitrani, 2020, COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors, Heart Rhythm, 17, 1984, 10.1016/j.hrthm.2020.06.026

Heusch, 2018, Coronary microembolization and microvascular dysfunction, Int J Cardiol, 258, 17, 10.1016/j.ijcard.2018.02.010

Bader, 2021, Heart failure and COVID-19, Heart Fail Rev, 26, 1, 10.1007/s10741-020-10008-2

Fu, 2020, Clinical characteristics of coronavirus disease 2019 ( COVID-19 ) in China : a systematic review and meta-analysis, J Infect, 80, 656

Kalra, 2020, SARS-CoV-2, ACE2, and hydroxychloroquine: cardiovascular complications, therapeutics, and clinical readouts in the current settings, Pathogens (Basel, Switzerland), 9, 546

Clerkin, 2020, COVID-19 and cardiovascular disease, Circulation, 2019, 1648, 10.1161/CIRCULATIONAHA.120.046941

Inciardi, 2020, Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 819, 10.1001/jamacardio.2020.1096

Harikrishnan, 2020, Cardiological society of India position statement on COVID-19 and heart failure, Indian Heart J, 72, 75, 10.1016/j.ihj.2020.04.012

Jamal, 2020, The cardiovascular complications of chimeric antigen receptor T cell therapy, Curr Hematol Malignan Rep, 15, 130, 10.1007/s11899-020-00567-4

Puntmann, 2020, Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 1265, 10.1001/jamacardio.2020.3557

Hua, 2020, Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19, Eur Heart J, 41, 2130, 10.1093/eurheartj/ehaa253

Kunal, 2020, Cardiovascular system and CoviD-19: perspectives from a developing country, Monaldi Arch Chest Dis, 90, 231, 10.4081/monaldi.2020.1305

Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China, J Am Med Assoc, 323, 1061, 10.1001/jama.2020.1585

Bansal, 2020, Cardiovascular disease and COVID-19, Diab Metab Syndr Clin Res Rev, 14, 247

Goha, 2020, COVID-19 and the heart: an update for clinicians, Clin Cardiol, 43, 1216, 10.1002/clc.23406

Kochi, 2020, Cardiac and arrhythmic complications in patients with COVID-19, J Cardiovasc Electrophysiol, 31, 1003, 10.1111/jce.14479

Park, 2020, In The eye of the storm: the right ventricle in COVID-19, Pulm Circ, 10, 10.1177/2045894020936660

Klok, 2020, Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19 : an updated analysis, Thromb Res, 1

Panigada, 2020, Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis, J Thromb Haemostasis, 18, 1738, 10.1111/jth.14850

Klok, 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res, 191, 145, 10.1016/j.thromres.2020.04.013

Bishop, 2017, 3-D bioprinting technologies in tissue engineering and regenerative medicine: current and future trends, Genes Dis, 4, 185, 10.1016/j.gendis.2017.10.002

Strang, 2013, Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis, Atherosclerosis, 229, 174, 10.1016/j.atherosclerosis.2013.04.031

Chen, 2008, Characterisation of a soft elastomer poly(glycerol sebacate) designed to match the mechanical properties of myocardial tissue, Biomaterials, 29, 47, 10.1016/j.biomaterials.2007.09.010

Wang, 2010, Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy, Adv Drug Deliv Rev, 62, 784, 10.1016/j.addr.2010.03.001

Jawad, 2008, Myocardial tissue engineering, Br Med Bull, 87, 31, 10.1093/bmb/ldn026

Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019

Taylor, 2001, Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure, Curr Contr Trials Cardiovasc Med, 2, 208, 10.1186/CVM-2-5-208

Rodrigues, 2018, Cardiac tissue engineering: current state-of-the-art materials, cells and tissue formation, Einstein (Sao Paulo, Brazil), 16, eRB4538

Asano, 2006, In vivo tumor formation from primate embryonic stem cells, Methods Mol Biol, 329, 459

Swijnenburg, 2005, Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium, Circulation, 112, 166

Cao, 2007, Spatial and temporal kinetics of teratoma formation from murine embryonic stem cell transplantation, Stem Cell Dev, 16, 883, 10.1089/scd.2007.0160

Wagers, 2004, Plasticity of adult stem cells, Cell, 116, 639, 10.1016/S0092-8674(04)00208-9

Herrerosa, 2003, Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction, Eur Heart J, 24, 2012, 10.1016/j.ehj.2003.09.012

Menasché, 2002, Myoblast transplantation: feasibility, safety and efficacy, Ann Med, 34, 314, 10.1080/078538902320772061

Mantakaki, 2018, Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease, PeerJ, 6, 10.7717/peerj.5805

Fujita, 2017, Myocardial tissue engineering for regenerative applications, Curr Cardiol Rep, 19, 10.1007/s11886-017-0892-4

Vunjak-Novakovic, 2010, Challenges in cardiac tissue engineering, Tissue Eng B Rev, 16, 169, 10.1089/ten.teb.2009.0352

Kofidis, 2003, Pulsatile perfusion and cardiomyocyte viability in a solid three-dimensional matrix, Biomaterials, 24, 5009, 10.1016/S0142-9612(03)00429-0

Dvir, 2006, A novel perfusion bioreactor providing a homogenous milieu for tissue regeneration, Tissue Eng, 12, 2843, 10.1089/ten.2006.12.2843

Dvir, 2007, Activation of the ERK1/2 cascade via pulsatile interstitial fluid flow promotes cardiac tissue assembly, Tissue Eng, 13, 2185, 10.1089/ten.2006.0364

Zimmermann, 2006, Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts, Nat Med, 12, 452, 10.1038/nm1394

Radisic, 2004, Medium perfusion enables engineering of compact and contractile cardiac tissue, Am J Physiol Heart Circ Physiol, 286, 507, 10.1152/ajpheart.00171.2003

Radisic, 2003, High-density seeding of myocyte cells for cardiac tissue engineering, Biotechnol Bioeng, 82, 403, 10.1002/bit.10594

Tandon, 2009, Electrical stimulation systems for cardiac tissue engineering, Nat Protoc, 4, 155, 10.1038/nprot.2008.183

Radisic, 2006, Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue, Biotechnol Bioeng, 93, 332, 10.1002/bit.20722

Yu, 2020, Current advances in 3D bioprinting technology and its applications for tissue engineering, Polymers (Basel), 12, 1, 10.3390/polym12122958

Birla, 2020, 3D bioprinting and its potential impact on cardiac failure treatment: an industry perspective, APL Bioeng, 4, 10.1063/1.5128371

Shahzadi, 2021, 3D bioprinting–a step towards heart tissue regeneration, J Appl Biotechnol Bioeng, 8, 1

Cui, 2018, 3D bioprinting for cardiovascular regeneration and pharmacology, Adv Drug Deliv Rev, 132, 252, 10.1016/j.addr.2018.07.014

Jang, 2017, 3D bioprinting and in vitro cardiovascular tissue modeling, Bioengineering, 4

Cui, 2017, 3D bioprinting for organ regeneration, Adv Healthc Mater, 6, 10.1002/adhm.201601118

Miller, 2012, Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues, Nat Mater, 11, 768, 10.1038/nmat3357

Park, 2010, Microporous cell-laden hydrogels for engineered tissue constructs, Biotechnol Bioeng, 106, 138

Garvin, 2010, Controlling the spatial organization of cells and extracellular matrix proteins in engineered tissues using ultrasound standing wave fields, Ultrasound Med Biol, 36, 1919, 10.1016/j.ultrasmedbio.2010.08.007

Garvin, 2011, Vascularization of three-dimensional collagen hydrogels using ultrasound standing wave fields, Ultrasound Med Biol, 37, 1853, 10.1016/j.ultrasmedbio.2011.07.008

Garvin, 2013, Spatial patterning of endothelial cells and vascular network formation using ultrasound standing wave fields, J Acoust Soc Am, 134, 1483, 10.1121/1.4812867

Comeau, 2017, Ultrasound patterning technologies for studying vascular morphogenesis in 3D, J Cell Sci, 130, 232

Alonzo, 2019, 3D Bioprinting of cardiac tissue and cardiac stem cell therapy, Transl Res, 211, 64, 10.1016/j.trsl.2019.04.004

Jian, 2018, 3D bioprinting for cell culture and tissue fabrication, Bio-des Manuf, 1, 45, 10.1007/s42242-018-0006-1